Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 361

1.

Short communication: Does interleukin-28B single nucleotide polymorphisms influence the natural history of hepatitis B?

Martín-Carbonero L, Rallón NI, Benito JM, Poveda E, González-Lahoz J, Soriano V.

AIDS Res Hum Retroviruses. 2012 Oct;28(10):1262-4. Epub 2012 Mar 23.

PMID:
22324878
2.

HCV-specific T-cell responses in HIV/hepatitis C virus-coinfected patients on highly active antiretroviral therapy are comparable to those observed in hepatitis C virus-monoinfected individuals.

Rallón NI, Soriano V, Restrepo C, García-Samaniego J, Labarga P, López M, Peris A, González-Lahoz J, Benito JM.

J Acquir Immune Defic Syndr. 2011 May 1;57(1):1-8.

PMID:
21786458
3.

Short communication: use of serum bilirubin levels as surrogate marker of early virological response to atazanavir-based antiretroviral therapy.

Morello J, Alvarez E, Cuenca L, Vispo E, González-Lahoz J, Soriano V, Rodríguez-Nóvoa S.

AIDS Res Hum Retroviruses. 2011 Oct;27(10):1043-5. doi: 10.1089/AID.2011.0019. Epub 2011 Mar 23.

PMID:
21348813
4.

Short communication: severe immune suppression in patients infected with R5-tropic HIV-1 strains is associated with increased gp120 net charge at variable regions.

Seclén E, Soriano V, del Mar González M, González-Lahoz J, Poveda E.

AIDS Res Hum Retroviruses. 2011 Sep;27(9):965-7. doi: 10.1089/AID.2010.0359. Epub 2011 Mar 13.

PMID:
21314481
5.

Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues.

Martín-Carbonero L, Teixeira T, Poveda E, Plaza Z, Vispo E, González-Lahoz J, Soriano V.

AIDS. 2011 Jan 2;25(1):73-9. doi: 10.1097/QAD.0b013e328340fde2.

PMID:
21076274
6.

Simplification from protease inhibitors to once- or twice-daily raltegravir: the ODIS trial.

Vispo E, Barreiro P, Maida I, Mena A, Blanco F, Rodríguez-Novoa S, Morello J, Jimenez-Nacher I, Gonzalez-Lahoz J, Soriano V.

HIV Clin Trials. 2010 Jul-Aug;11(4):197-204. doi: 10.1310/hct1104-197.

PMID:
20974575
7.

Treatment of chronic hepatitis C in HIV-infected patients with compensated liver cirrhosis.

Martín-Carbonero L, Tuma P, Vispo E, Medrano J, Labarga P, González-Lahoz J, Barreiro P, Soriano V.

J Viral Hepat. 2011 Aug;18(8):542-8. doi: 10.1111/j.1365-2893.2010.01334.x. Epub 2010 Aug 31.

PMID:
20819149
8.

High sensitivity of specific genotypic tools for detection of X4 variants in antiretroviral-experienced patients suitable to be treated with CCR5 antagonists.

Seclén E, Garrido C, González Mdel M, González-Lahoz J, de Mendoza C, Soriano V, Poveda E.

J Antimicrob Chemother. 2010 Jul;65(7):1486-92. doi: 10.1093/jac/dkq137. Epub 2010 Apr 28.

PMID:
20427374
9.

The benefit of simplification from tipranavir/ritonavir 500/200 bid to 500/100 bid guided by therapeutic drug monitoring.

Morello J, Rodríguez-Novoa S, Blanco F, Vispo E, Barreiro P, Gonzalez-Pardo G, Jiménez-Nácher I, González-Lahoz J, Soriano V.

Ther Drug Monit. 2010 Apr;32(2):242-4. doi: 10.1097/FTD.0b013e3181d3f97f.

PMID:
20216112
10.

Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C.

Morello J, Soriano V, Barreiro P, Medrano J, Madejón A, González-Pardo G, Jiménez-Nácher I, González-Lahoz J, Rodríguez-Novoa S.

Antimicrob Agents Chemother. 2010 Apr;54(4):1647-9. doi: 10.1128/AAC.01399-09. Epub 2010 Jan 25.

11.

Differences in liver fibrosis and response to pegylated interferon plus ribavirin in HIV/HCV-coinfected patients with normal vs elevated liver enzymes.

Maida I, Martin-Carbonero L, Sotgiu G, Vispo E, Barreiro P, Gonzalez-Lahoz J, Soriano V.

J Viral Hepat. 2010 Dec;17(12):866-71. doi: 10.1111/j.1365-2893.2009.01260.x.

PMID:
20088891
12.

Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance.

Blanco F, Barreiro P, Ryan P, Vispo E, Martín-Carbonero L, Tuma P, Labarga P, Medrano J, González-Lahoz J, Soriano V.

J Viral Hepat. 2011 Jan;18(1):11-6. doi: 10.1111/j.1365-2893.2009.01261.x.

PMID:
20088890
13.

[The challenge of the new H1N1 influenza A].

Soriano V, González-Lahoz J.

Med Clin (Barc). 2009 Nov 14;133(18):708-9. doi: 10.1016/j.medcli.2009.09.036. Spanish. No abstract available.

PMID:
19883804
14.

[Malignancies in HIV infected patients: study of 139 cases].

Ramírez-Olivencia G, Valencia-Ortega ME, Martin-Carbonero L, Moreno-Celda V, González-Lahoz J.

Med Clin (Barc). 2009 Nov 21;133(19):729-35. doi: 10.1016/j.medcli.2009.03.043. Epub 2009 Oct 31. Spanish.

PMID:
19880148
15.

Use of different inhibitory quotients to predict early virological response to tipranavir in antiretroviral-experienced human immunodeficiency virus-infected patients.

Morello J, De Mendoza C, Soriano V, Anta L, González-Pardo G, Corral A, Blanco F, Jiménez-Nácher I, González-Lahoz J, Rodríguez-Novoa S.

Antimicrob Agents Chemother. 2009 Oct;53(10):4153-8. doi: 10.1128/AAC.00041-09. Epub 2009 Jul 13.

16.

Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection.

Martin-Carbonero L, de Ledinghen V, Moreno A, Maida I, Foucher J, Barreiro P, Romero M, Satta G, Garcia-Samaniego J, Gonzalez-Lahoz J, Soriano V.

J Viral Hepat. 2009 Nov;16(11):790-5. doi: 10.1111/j.1365-2893.2009.01133.x. Epub 2009 Apr 28.

PMID:
19413693
17.

Liver complications have reached a plateau as cause of hospital admission and death in HIV patients in Madrid.

Núñez-Fernández C, Martín-Carbonero L, Valencia ME, Aguilera J, García-Samaniego J, Gonzalez-Lahoz J, Soriano V.

AIDS Res Hum Retroviruses. 2009 Apr;25(4):383-5. doi: 10.1089/aid.2008.0242.

PMID:
19320566
18.

Design and validation of new genotypic tools for easy and reliable estimation of HIV tropism before using CCR5 antagonists.

Poveda E, Seclén E, González Mdel M, García F, Chueca N, Aguilera A, Rodríguez JJ, González-Lahoz J, Soriano V.

J Antimicrob Chemother. 2009 May;63(5):1006-10. doi: 10.1093/jac/dkp063. Epub 2009 Mar 3.

PMID:
19261623
19.

Level, phenotype and activation status of CD4+FoxP3+ regulatory T cells in patients chronically infected with human immunodeficiency virus and/or hepatitis C virus.

Rallón NI, López M, Soriano V, García-Samaniego J, Romero M, Labarga P, García-Gasco P, González-Lahoz J, Benito JM.

Clin Exp Immunol. 2009 Jan;155(1):35-43. doi: 10.1111/j.1365-2249.2008.03797.x.

20.

Predictors of severe hepatic steatosis using abdominal ultrasound in HIV-infected patients.

Ryan P, Blanco F, García-Gascó P, García-Merchán J, Vispo E, Barreiro P, Labarga P, González-Lahoz J, Soriano V.

HIV Med. 2009 Jan;10(1):53-9. doi: 10.1111/j.1468-1293.2008.00651.x. Epub 2008 Nov 10.

21.

Increase in serum bilirubin in HIV/hepatitis-C virus-coinfected patients on atazanavir therapy following initiation of pegylated-interferon and ribavirin.

Rodríguez-Nóvoa S, Morello J, González M, Vispo E, Barreiro P, González-Pardo G, Jiménez-Nácher I, Gonzalez-Lahoz J, Soriano V.

AIDS. 2008 Nov 30;22(18):2535-7. doi: 10.1097/QAD.0b013e3283177f38.

PMID:
19005277
22.
23.

HIV rebound after discontinuation of antiretroviral therapy increases and expands HIV-specific CD8+ responses but has no impact on its functionality.

López M, Rallón N, Soriano V, Rodríguez I, Valencia E, Labarga P, Moreno V, Vispo E, Roncal F, González-Lahoz J, Benito JM.

AIDS Res Hum Retroviruses. 2008 Sep;24(9):1197-201. doi: 10.1089/aid.2008.0088.

PMID:
18788910
24.

No major differences in the functional profile of HIV Gag and Nef-specific CD8+ responses between long-term nonprogressors and typical progressors.

López M, Soriano V, Lozano S, Ballesteros C, Cascajero A, Rodés B, De La Vega E, González-Lahoz J, Benito JM.

AIDS Res Hum Retroviruses. 2008 Sep;24(9):1185-95. doi: 10.1089/aid.2008.0006.

PMID:
18729773
25.

Long-term prognosis of HIV-infected patients with Kaposi sarcoma treated with pegylated liposomal doxorubicin.

Martín-Carbonero L, Palacios R, Valencia E, Saballs P, Sirera G, Santos I, Baldobí F, Alegre M, Goyenechea A, Pedreira J, González del Castillo J, Martínez-Lacasa J, Ocampo A, Alsina M, Santos J, Podzamczer D, González-Lahoz J; Caelyx/Kaposi's Sarcoma Spanish Group.

Clin Infect Dis. 2008 Aug 1;47(3):410-7. doi: 10.1086/589865.

PMID:
18582203
26.

Trends in the prescription of antiretroviral drugs and impact on plasma HIV-RNA measurements.

Jiménez-Nácher I, García B, Barreiro P, Rodriguez-Novoa S, Morello J, González-Lahoz J, de Mendoza C, Soriano V.

J Antimicrob Chemother. 2008 Oct;62(4):816-22. doi: 10.1093/jac/dkn252. Epub 2008 Jun 21.

PMID:
18567912
27.

Changing patterns in HIV reverse transcriptase resistance mutations after availability of tenofovir.

de Mendoza C, Jiménez-Nacher I, Garrido C, Barreiro P, Poveda E, Corral A, Zahonero N, González-Lahoz J, Soriano V.

Clin Infect Dis. 2008 Jun 1;46(11):1782-5. doi: 10.1086/588045.

PMID:
18426370
28.

Suppression of viral replication with highly active antiretroviral therapy has no impact on the functional profile of HIV-specific CD8(+) T cells.

López M, Soriano V, Rallón N, Cascajero A, González-Lahoz J, Benito JM.

Eur J Immunol. 2008 Jun;38(6):1548-58. doi: 10.1002/eji.200738054.

29.

Subtype variability, virological response and drug resistance assessed on dried blood spots collected from HIV patients on antiretroviral therapy in Angola.

Garrido C, Zahonero N, Fernándes D, Serrano D, Silva AR, Ferraria N, Antúnes F, González-Lahoz J, Soriano V, de Mendoza C.

J Antimicrob Chemother. 2008 Mar;61(3):694-8. doi: 10.1093/jac/dkm515. Epub 2008 Jan 24.

PMID:
18218644
30.

Episodes of low-level viral rebound in HIV-infected patients on antiretroviral therapy: frequency, predictors and outcome.

García-Gascó P, Maida I, Blanco F, Barreiro P, Martín-Carbonero L, Vispo E, González-Lahoz J, Soriano V.

J Antimicrob Chemother. 2008 Mar;61(3):699-704. doi: 10.1093/jac/dkm516. Epub 2008 Jan 12.

PMID:
18192682
31.

Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards.

Rodríguez-Nóvoa S, García-Gascó P, Blanco F, González-Pardo G, Castellares C, Moreno V, Jiménez-Nácher I, González-Lahoz J, Soriano V.

AIDS Res Hum Retroviruses. 2007 Nov;23(11):1374-6. doi: 10.1089/aid.2006.0244.

PMID:
18184080
32.

Efficacy and safety of replacing lopinavir with atazanavir in HIV-infected patients with undetectable plasma viraemia: final results of the SLOAT trial.

Soriano V, García-Gasco P, Vispo E, Ruiz-Sancho A, Blanco F, Martín-Carbonero L, Rodríguez-Novoa S, Morello J, de Mendoza C, Rivas P, Barreiro P, González-Lahoz J.

J Antimicrob Chemother. 2008 Jan;61(1):200-5. Epub 2007 Nov 13.

PMID:
17999977
33.

Efficacy and safety of a once daily regimen with efavirenz, lamivudine, and didanosine, with and without food, as initial therapy for HIV Infection: the ELADI study.

Sánchez-Conde M, Palacios R, Sanz J, Rodríguez-Novoa S, Rivas P, Santos J, Sola J, Asensi V, de Mendoza C, Estrada V, Barreiro P, González-Lahoz J, Jiménez-Nacher I, Soriano V.

AIDS Res Hum Retroviruses. 2007 Oct;23(10):1237-41.

PMID:
17961110
34.

Prevalence of etravirine (TMC-125) resistance mutations in HIV-infected patients with prior experience of non-nucleoside reverse transcriptase inhibitors.

Poveda E, Garrido C, de Mendoza C, Corral A, Cobo J, González-Lahoz J, Soriano V.

J Antimicrob Chemother. 2007 Dec;60(6):1409-10. Epub 2007 Oct 3. No abstract available.

PMID:
17913723
35.

Update on the treatment of chronic hepatitis C in HIV-infected patients.

Soriano V, Barreiro P, Martin-Carbonero L, Vispo E, Garcia-Samaniego J, Labarga P, Gonzalez-Lahoz J.

AIDS Rev. 2007 Apr-Jun;9(2):99-113. Review.

PMID:
17694677
36.

Changing rates and patterns of drug resistance mutations in antiretroviral-experienced HIV-infected patients.

de Mendoza C, Garrido C, Corral A, Ramírez-Olivencia G, Jiménez-Nacher I, Zahonero N, Gonzalez-Lahoz J, Soriano V.

AIDS Res Hum Retroviruses. 2007 Jul;23(7):879-85.

PMID:
17678470
37.

Evolution of T-cell responses to hepatitis C virus (HCV) during pegylated interferon plus ribavirin treatment in HCV-monoinfected and in HCV/HIV-coinfected patients.

Capa L, Soriano V, García-Samaniego J, Nuñez M, Romero M, de Mendoza C, Cascajero A, Muñoz F, González-Lahoz J, Benito JM.

Antivir Ther. 2007;12(4):459-68.

PMID:
17668554
38.

Prevalence of darunavir resistance mutations in HIV-1-infected patients failing other protease inhibitors.

Poveda E, de Mendoza C, Martin-Carbonero L, Corral A, Briz V, González-Lahoz J, Soriano V.

J Antimicrob Chemother. 2007 Oct;60(4):885-8. Epub 2007 Jul 23.

PMID:
17646201
39.

Prevalence of X4 tropic HIV-1 variants in patients with differences in disease stage and exposure to antiretroviral therapy.

Poveda E, Briz V, de Mendoza C, Benito JM, Corral A, Zahonero N, Lozano S, González-Lahoz J, Soriano V.

J Med Virol. 2007 Aug;79(8):1040-6.

PMID:
17596837
40.

Hydroxyurea exerts an anti-proliferative effect on T cells but has no direct impact on cellular activation.

Benito JM, López M, Lozano S, Ballesteros C, González-Lahoz J, Soriano V.

Clin Exp Immunol. 2007 Jul;149(1):171-7. Epub 2007 May 18.

41.

Clearance of hepatitis C virus in HIV-infected patients with multiple chronic viral hepatitis.

Martín-Carbonero L, Barreiro P, Jiménez-Galán G, García-Berriguete R, Núñez M, Ríos P, González-Lahoz J, Soriano V.

J Viral Hepat. 2007 Jun;14(6):392-5.

PMID:
17501759
42.

Influence of HCV genotype and co-infection with human immunodeficiency virus on CD4(+) and CD8(+) T-cell responses to hepatitis C virus.

Capa L, Soriano V, García-Samaniego J, Nuñez M, Romero M, Cascajero A, Muñoz F, González-Lahoz J, Benito JM.

J Med Virol. 2007 May;79(5):503-10.

PMID:
17385690
43.

Treatment of chronic hepatitis B or C in HIV-infected patients with dual viral hepatitis.

Soriano V, Barreiro P, Martín-Carbonero L, Castellares C, Ruiz-Sancho A, Labarga P, Ramos B, Gonzalez-Lahoz J.

J Infect Dis. 2007 Apr 15;195(8):1181-3. Epub 2007 Mar 2.

PMID:
17357055
44.

[Immigration and HIV-1 infection: clinical manifestations, subtypes and evolution of 78 patients attended during the last 5 years].

Valencia Ortega ME, Holguín Fernández A, Moreno Celda V, Alvarez Ferrero A, Lago Núñez M, González Lahoz J.

Med Clin (Barc). 2007 Mar 3;128(8):302-4. Spanish.

PMID:
17338863
45.

Influence of liver fibrosis stage on plasma levels of antiretroviral drugs in HIV-infected patients with chronic hepatitis C.

Barreiro P, Rodríguez-Novoa S, Labarga P, Ruiz A, Jiménez-Nácher I, Martín-Carbonero L, Gonzalez-Lahoz J, Soriano V.

J Infect Dis. 2007 Apr 1;195(7):973-9. Epub 2007 Feb 20.

PMID:
17330787
46.

Mitochondrial DNA depletion in HIV-infected patients with chronic hepatitis C and effect of pegylated interferon plus ribavirin therapy.

de Mendoza C, Martin-Carbonero L, Barreiro P, de Baar M, Zahonero N, Rodriguez-Novoa S, Benito JM, González-Lahoz J, Soriano V.

AIDS. 2007 Mar 12;21(5):583-8.

PMID:
17314520
47.

Sustained virological response following HCV therapy is associated with non-progression of liver fibrosis in HCV/HIV-coinfected patients.

Barreiro P, Labarga P, Martín-Carbonero L, Amor A, Ruiz-Sancho A, Castellares C, González-Lahoz J, Soriano V.

Antivir Ther. 2006;11(7):869-77.

PMID:
17302249
48.

Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients.

Martín-Carbonero L, Gil P, García-Benayas T, Barreiro P, Blanco F, de Mendoza C, Maida I, González-Lahoz J, Soriano V.

AIDS Res Hum Retroviruses. 2006 Dec;22(12):1231-5.

PMID:
17209764
49.

Liver fibrosis in HIV-infected patients with chronic hepatitis B extensively exposed to antiretroviral therapy with anti-HBV activity.

Maida I, Soriano V, Castellares C, Ramos B, Sotgiu G, Martin-Carbonero L, Barreiro P, Rivas P, González-Lahoz J, Núñez M.

HIV Clin Trials. 2006 Sep-Oct;7(5):246-50.

PMID:
17162318
50.

Genetic factors influencing atazanavir plasma concentrations and the risk of severe hyperbilirubinemia.

Rodríguez-Nóvoa S, Martín-Carbonero L, Barreiro P, González-Pardo G, Jiménez-Nácher I, González-Lahoz J, Soriano V.

AIDS. 2007 Jan 2;21(1):41-6.

PMID:
17148966

Supplemental Content

Loading ...
Support Center